Quality of life and vasculitis Archives

Abstract Number: 2973 • ACR/ARHP Annual Meeting 2016
A Comparison of Caregiving Burden and Impact in Systemic Vasculitis Versus Other Conditions
Matthew Gray¹, Delesha M. Carpenter², Lorie L. Geryk³, Courtney A. Roberts⁴, Joshua M. Thorpe⁵, Tao Jiang⁵, Susan L Hogan⁶ and Carolyn T. Thorpe⁵, ¹University of Pittsburgh, Pittsburgh, PA, ²Division of Pharmaceutical Outcomes and Policy, University of North Carolina, Asheville, NC, ³Division of Pharmaceutical Outcomes and Policy, University of North Carolina, Chapel Hill, NC, ⁴Division of Pharmaceutical Outcomes and Policy, University of North Carolina Eshelman School of Pharmacy, Chapel Hill, NC, ⁵School of Pharmacy, University of Pittsburgh, Pittsburgh, PA, ⁶UNC Kidney Center, Chapel Hill, NC
Background/Purpose: Serving as an informal caregiver to a family member or friend with a chronic illness is associated with stress, reduced health status, and financial…
Abstract Number: 3046 • ACR/ARHP Annual Meeting 2015
Venous Disease-Specific Quality-of-Life Is Impaired in Patients with Vascular Behcet’s Disease
Fatma Alibaz-Oner¹, Belgin Aldag², Mustafa Aldag³, Ali Ugur Unal⁴, Tayfur Toptas⁵, Tülin Ergun⁶ and Haner Direskeneli⁴, ¹Department Rheumatology, Marmara University Faculty of Medicine, Istanbul, Turkey, ²Rheumatology, Marmara University, School of Medicine, Istanbul, Turkey, ³Dr.Siyami Ersek Cardiovascular Surgery Hospital,, Istanbul, Turkey, ⁴Department of Rheumatology, Marmara University Faculty of Medicine, Istanbul, Turkey, ⁵Hematology, Marmara University, Istanbul, Turkey, ⁶Dermatology, Marmara University Faculty of Medicine, Dermatology, Istanbul, Turkey
Background/Purpose: Vascular involvement is seen in up to 40% of the patients with Behcet's disease (BD), with lower extremity deep vein thrombosis (DVT) as the most…
Abstract Number: 1778 • ACR/ARHP Annual Meeting 2014
Rituximab Versus Azathioprine for ANCA-Associated Vasculitis Maintenance Therapy: Impact in Health-Related Quality of Life
Grégory Pugnet^1,2, Christian Pagnoux³, Alexandre Karras⁴, Chahéra Khouatra⁵, Olivier Aumaître⁶, Pascal Cohen¹, Francois Maurier⁷, Olivier Decaux⁸, Jacques Ninet⁹, Pierre Gobert¹⁰, Thomas Quemeneur¹¹, Claire Blanchard-Delaunay¹², Pascal Godmer¹³, Xavier Puéchal¹, Pierre-Louis Carron¹⁴, Pierre-Yves Hatron¹⁵, Nicolas Limal¹⁶, Mohamed Hamidou¹⁷, Eric Daugas¹⁸, Thomas Papo¹⁹, Bernard Bonnotte²⁰, Alfred Mahr²¹, Benjamin Terrier¹, Philippe Ravaud²², Luc Mouthon¹ and Loïc Guillevin¹, ¹National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, Paris, France, ²Toulouse University Hospital, Internal Medicine Department, Toulouse, France, ³Division of Rheumatology, University of Toronto, Toronto, ON, Canada, ⁴Nephrology, Hôpital Européen Georges Pompidou, APHP, Paris, France, ⁵CHU Louis Pradel, Lyon, Lyon, France, ⁶Division of internal Medicine, Centre Hospitalier Universitaire, Hôpital Gabriel Montpied, Clermont–Ferrand, Clermont–Ferrand, France, ⁷HP Metz Belle Isle Hospital, Department of Internal Medicine, Metz, France, ⁸Department of Internal Medicine, Rennes University Hospital, Rennes, France, ⁹Department of Nephrology and Internal Medicine, Hôpital Edouard Herriot, Lyon, France, Lyon, France, ¹⁰Nephrology, Centre Hospitalier d'Avignon, Avignon, France, ¹¹Internal Medicine, CH, Valenciennes, France, ¹²Internal Medicine, Hôpital de Niort, Niort, France, ¹³Department of Internal Medicine, Centre Hospitalier Bretagne Atlantique de Vannes, Vannes, France, ¹⁴Internal Medicine, Centre Hospitalier de Grenoble, Grenoble, France, ¹⁵CHU Lille, Lille, France, ¹⁶Department of Internal Medicine, Hôpital Henri Mondor, APHP, Creteil, France, ¹⁷CHU Hôtel Dieu, Nantes, Nantes, France, ¹⁸Internal Medicine, AP-HP Hôpital Bîchat, Paris, France, ¹⁹Internal Medicine, Bichat Hospital, Paris, Paris, France, ²⁰Dijon University Hospital, INSERM UMR 1098, Besançon ; University of Burgundy, Faculty of Medicine, IFR100 ; Department of Internal Medicine and Clinical Immunology, Dijon, France, ²¹Internal Medicine, Hospital Saint-Louis, University Paris 7, Paris, France, ²²Epidemiology, AP-HP Cochin Hospital, Paris, France
Background/Purpose A key goal in the management of ANCA-Associated Vasculitis (AAV) is to improve and preserve health-related quality of life (HRQOL). Several studies have found that…
Abstract Number: 1525 • ACR/ARHP Annual Meeting 2012
Determinants of Poor Quality of Life in ANCA Associated Vasculitis (AAV)
Neil Basu¹, Andrew McClean², Raashid A. Luqmani³, Lorraine Harper², Oliver Flossmann⁴, David Jayne⁵, Mark Little⁶, Esther N. Amft⁷, Neeraj Dhaun⁸, John McLaren⁹, Vinod Kumar¹⁰, Lars Erwig¹¹, Gareth T. Jones¹, David M. Reid¹² and Gary J. Macfarlane¹, ¹Musculoskeletal Research Collaboration (Epidemiology Group), University of Aberdeen, Aberdeen, United Kingdom, ²Nephrology, University of Birmingham, Birmingham, United Kingdom, ³Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Science, University of Oxford, Oxford, United Kingdom, ⁴Nephrology, Royal Berkshire Hospital, Reading, United Kingdom, ⁵Vasculitis and Lupus Clinic, Addenbrookes Hospital University of Cambridge, Cambridge, United Kingdom, ⁶Clinical Medicine, Trinity College Dublin, Dublin, Ireland, ⁷Rheumatic Diseases Unit, Western General Hospital, Edinburgh, United Kingdom, ⁸Nephrology, Edinburgh Royal Infirmary, Edinburgh, United Kingdom, ⁹Fife Rheumatic Diseases Unit, NHS Fife, Whyteman's Brae Hospital, Kirkcaldy, United Kingdom, ¹⁰Rheumatology, Ninewells Hospital, Dundee, United Kingdom, ¹¹Division of Applied Medicine, University of Aberdeen, Aberdeen, United Kingdom, ¹²Musculoskeletal Research Collaboration (Medicine & Therapeutics), University of Aberdeen, Aberdeen, United Kingdom
Determinants of Poor Quality of Life in ANCA Associated Vasculitis (AAV) Background/Purpose : Patients with ANCA associated vasculitis (AAV) report significantly reduced quality of life (QOL),…

Abstracts tagged "Quality of life and vasculitis"

A Comparison of Caregiving Burden and Impact in Systemic Vasculitis Versus Other Conditions

Venous Disease-Specific Quality-of-Life Is Impaired in Patients with Vascular Behcet’s Disease

Rituximab Versus Azathioprine for ANCA-Associated Vasculitis Maintenance Therapy: Impact in Health-Related Quality of Life

Determinants of Poor Quality of Life in ANCA Associated Vasculitis (AAV)